|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical Relevance of urokinase-type plasminogen activator,its receptor, and its inhibitor type 1 in endometrial cancer显示文摘 | TECIMER C DOERING D L GOLDSMITH L J | 2001 | Gynecol Oncol2001，80，1： | 1 |
| 2 | Clinical relevance of urokinase-type plasminogen activator,its receptor and inhibitor type 1 in ovarian cancer显示文摘 | Tecimer C Doering D L Goldsmith L J | 2000 | Int J Gynecol Cancer2000，10，5： | 1 |
| 3 | Clinical relevance of urokinase- type plasminogen activator,its receptor, and its inhibitor type 1 in endometrial cancer显示文摘 | Tecimer C Doefing DL Goldsmith LJ | 2001 | Gynecol Oncol2001，80，1： | 1 |
| 4 | Clinical relevance of urokinase-type plasminogen activator,its receptor,and its inhibitor type I in endometrial cancer显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2001 | Gynecol Oncol2001，80，1： | 1 |
| 5 | Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endome-trial cancer显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2001 | Gynecol Oncol2001，80，1： | 1 |
| 6 | Clinical relevance of urokinase-type plasminogen activator,its receptor and inhibitor type 1 in ovarian cancer显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2000 | Int J Gynecol Cancer2000，10，5： | 1 |
| 7 | Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer 显示文摘 | Tecimer C Doering DL Goldsmith LJ Meyer JS Abdulhay G Wittliff JL | 2000 | Int J Gynccol Cancer2000，10，5： | 1 |
| 8 | Clinical relevance of urokinase - type plasminogen activator,its receptor and inhibitor type 1 in ovarian cancer 显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2000 | Int J Gynecol Cancer2000，10，5： | 1 |
| 9 | Clinical relevance of urokinase-type plasminegen activator,its receptor,and its in-hibitor type 1 in endometrial cancer显示文摘 | Doerieg DL Goldsmith LJ | 2001 | Gynecol Oncol2001，80，1： | 1 |
| 10 | Clinical revelence of urokinase-type plasminogen activator,its receptor and inhibitor type-1 in ovarion cancer显示文摘 | TECIMER C DOERING D L GOLDSMITH L J | 2000 | Int J Gynecol Cancer2000，10，5： | 1 |
| 11 | Chnical relevance of urokinase-type plasminogen activator, its receptor and inhibitor typel in ovarianc ancer显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2000 | Int J Gynecol Cancer2000，10，5： | 1 |
| 12 | Clinical relevance of urokinase - type plasminogan activator, its receptor, and its inhibitor type 1 in endometrial cancer 显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2001 | Gynecal Oncol2001，80，1： | 1 |
| 13 | Clinical relevance of urokinase-type plasminogen activator,its receptor,and its inhibitor type 1 in endometrial cancer显示文摘 | Tecimer C Doering DL Goldsmith LJ | 2001 | Gynecol Oncol2001，80，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员